Atlas Trials

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Clinical trial NCT07047586 · RECRUITING

Trial details

NCT number
NCT07047586
Sponsor
Fudan University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2025-07-02
Primary completion
2028-06-30
Enrollment
146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.